Background--Poor adherence to medications is a common problem among heart failure (HF) patients. Inadequate adherence leads to increased HF exacerbations, reduced physical function, and higher risk for hospital admission and death. Many interventions have been tested to improve adherence to HF medications, but the overall impact of such interventions on readmissions and mortality is unknown.
O ver 5.7 million persons in the United States and at least 23 million people worldwide live with heart failure (HF), [1] [2] [3] which is associated with considerable morbidity, mortality, and health care costs. Cardiovascular disease remains the leading cause of death in the United States. 4, 5 Mortality rates among HF patients, in particular, are high. Of all deaths in the United States in 2009 (from any cause), 11% listed HF as a cause or contributing factor. 6 HF hospitalization rates also remain high, with over 1 million hospital discharges for HF in 2010, a rate essentially unchanged since 2000. 3, 7 Whereas HF is often considered a problem of the elderly, the rate of hospitalizations for HF patients under age 65 has significantly increased as well, 8 and despite efforts to prevent or delay the onset of cardiovascular disease, the prevalence of HF continues to rise. 2, 3 HF patients are taught self-care strategies to help manage symptoms, maintain physical functioning, and prevent symptom exacerbations and worsening of disease that could lead to hospitalization or death. Medication is a critical part of HF treatment, and adhering to medication regimens is a key behavior in HF self-care. Unfortunately, adherence among patients with HF is low, negatively affecting clinical outcomes and leading to increased HF exacerbations, reduced physical function, and higher risk for hospital admission and death. [9] [10] [11] Many interventions have been tested to improve adherence to medication among HF patients, but the overall impact of these interventions on patient mortality and hospital readmissions is not known. Previous reviews have only synthesized very few studies and may not accurately reflect the overall state of the literature. This article reports the results of a comprehensive systematic review and metaanalysis of mortality and hospitalization outcomes from HF medication adherence (MA) intervention studies.
Methods
This research synthesis used well-established systematic review the and meta-analysis methods, with reporting according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. [12] [13] [14] The project protocol is available from the primary author upon request.
Study Eligibility
Studies of adults (age ≥18 years) testing interventions to improve adherence to medications among patients with a diagnosis of HF were eligible for inclusion in the meta-analysis. Studies of patients who were institutionalized or otherwise not involved with administering their own medications were excluded. Both published and unpublished studies were included in order to analyze as comprehensive a sample of studies as possible. Searches were not limited by language; potentially eligible studies warranting further review were translated into English as necessary. Studies were not initially excluded based on study design or any a priori measure of study quality. In meta-analyses, two-group studies are analyzed separately from any single-group (pre-post) studies. Only 1 single-group study met the eligibility and outcome criteria for this project. As a result, this analysis focuses only on those studies with 2-group (ie, intervention vs control) comparisons.
Search Strategies and Information Sources
Multiple search strategies were employed to identify as many eligible studies as possible. Electronic database searches were developed and carried out by a health sciences research librarian on the research team. Databases searched included Table 1 for a sample search strategy. Further search methods included hand searching of selected journals for the previous 10 years to identify studies that may not have been located through electronic database searching. Reference lists of review articles were searched to identify further studies, and author searches were conducted on the names of primary investigators of eligible studies.
Research registries, such as clinicaltrials.gov, and conference proceedings were also searched to identify studies that had been conducted but not reported in an indexed source.
Each search result was evaluated for eligibility by 2 research staff. The full text of any studies deemed potentially eligible in the initial screening were evaluated to determine final eligibility. Every eligible study was independently coded and entered into separate databases by 2 trained research staff. Data were compared to reach 100% agreement on all coding items to ensure data accuracy. If a study report did not include sufficient data for calculating an effect size (ES), the study authors were contacted and asked to provide the necessary information.
Risk of Bias
Studies were not evaluated a priori for study quality or risk of bias, because no validated tools for this exist and require subjective evaluation by evaluators. Rather, the research team coded study characteristics that are typically considered to be quality indicators (eg, randomization, use of intention-to-treat, blinding of data collectors, study attrition, etc) and analyzed them empirically by moderator analyses. In this way, rather than excluding studies for perceived methodological flaws, we could determine whether indicators of risk for bias actually affected ES.
Statistical Analyses
Analyses were performed using Comprehensive Meta-Analysis software (Biostat, Inc., Englewood, NJ). A relative risk (RR) ES was calculated for each study reporting mortality outcomes. Whereas we are reporting RR for hospitalization outcomes, not all studies provided sufficient data for calculating RR, but all studies did report sufficient data for calculating an odds ratio (OR). Therefore, we are reporting both RR and OR ES measures for hospitalization outcomes.
For studies testing more than 1 intervention and sharing the same control group, we followed procedures established by the Cochrane Collaboration as well as Borenstein, Cooper, and colleagues by merging intervention groups to avoid dependency among comparisons in the meta-analysis. [13] [14] [15] Study ESs were pooled using a random-effects model. The random-effects model was chosen because of the expected heterogeneity across samples and across studies testing different types of adherence interventions. Substantial heterogeneity is expected in health behavior research. Each individual study ES was weighted by the inverse of its total variance (the study's sampling variance plus the calculated between-study variance, or Τ 2 ). Studies with significant standardized residuals were examined as potential outliers. Heterogeneity across the studies was assessed using the heterogeneity statistic, Q, as well as I 2 , which is a "signal-to-noise" ratio indicating the proportion of between-study heterogeneity in the metaanalysis. We assessed for publication bias by visual examination of funnel plots (see Figures 1 and 2 ). Moderator analyses were conducted for potential moderator variables that were present in a sufficient number of studies to further explain heterogeneity across studies, compare effects between different subgroups, and evaluate the impact of potential sources of bias. We used metaregression for continuous variables and a meta-analytic analogue of ANOVA for categorical variables. Moderator analyses were conducted on study characteristics (such as year of publication or whether a study reported a funding source), sample characteristics (mean age, sex, and race/ethnicity), and intervention characteristics. Results Literature searching resulted in 6665 citations of potentially eligible studies. Of those, 234 were screened as being eligible for full-text review, and 57 studies fulfilled the inclusion criteria for this meta-analysis (see Figure 3) . Mortality outcomes were reported for 48 studies. Hospitalization/ readmission outcomes were reported for 43 studies.
Primary Study Characteristics
Studies in the sample were published between 1996 and 2013. Attributes for each study are reported in Table 2 , and study demographics are summarized in Table 3 . Study participants were largely older, with mean sample ages ranging from 45 to 80 years (median, 70.4). Information on type of HF was inconsistently reported in the primary studies.
In those studies that did report the type of HF, the sample consisted entirely or predominantly of patients with reduced ejection fraction. Studies had a median sample size of 197. Whereas many of the studies reported some degree of attrition between randomization and final follow-up, all but 3 reported mortality and/or hospitalization outcomes for all randomized subjects, even if other measures were not collected for subjects lost to follow-up.
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Interventions in the Reviewed Studies
Intervention descriptions across the eligible studies varied widely in degree of detail. A bulk of the interventions utilized medication education (s=50) and disease education (s=48) as components of their interventions. In addition to using educational approaches, 14 interventions improved integration of care for HF patients and 11 attempted to get patients to incorporate self-management strategies in some manner. Another common intervention strategy was self-monitoring. Eight interventions had patients self-monitor their medicationtaking behavior by using a medication diary or other means, whereas 28 interventions encouraged patient self-monitoring of HF signs or symptoms. All but 4 interventions used multiple intervention strategies to improve adherence. The singlestrategy approaches involved disease education (s=2), dose modification (s=1), and a patient web portal (s=1). Although most studies used medication education in combination with other strategies, no other distinct patterns of intervention component combinations emerged. Fifty-two interventions involved some degree of face-toface contact with an interventionist. Many interventions involved interventionists from more than 1 discipline. Of those that specified the interventionist profession, 40 used nurses (including 5 using advanced practice nurses), 14 used pharmacists, 15 used physicians, 7 had dieticians, 6 had social workers, 1 had a case manager, and 4 employed unspecified health care providers. Only 4 studies had interventions delivered by the patients' regular health care providers.
Information about intervention dose was poorly reported across the studies. Only 28 studies clearly reported the number of intervention sessions (median=6.5 sessions; range, 1-52). Six studies reported the number of minutes per session (median=48.75; range, 10-120). Interventions were delivered over a median of 181 days (s=48; range, 1-901).
Nearly all interventions incorporated some form of verbal interaction in which interventionists talked to patients about their HF or HF medication. Thirty-eight interventions were delivered partly over the telephone. Fewer used telehealth (s=2), text messaging (s=2), computer delivery (s=4), video (s=6), or mailed intervention materials (s=4).
Meta-Analysis of Study Outcomes
Forty-eight studies reported sufficient data for calculating mortality outcome ESs (see Figure 4) . Random-effects metaanalysis found that mortality risk was 10.6% lower among HF patients who received MA interventions when compared to control groups (RR, 0.89; 95% CI, 0.81, 0.99). The pooled analysis yielded low, but significant, heterogeneity, with a Qstatistic of 67.46 (P=0.027) and an I 2 of 30.33. When 2 studies with significant residuals were removed to test for potential outliers, RR was essentially unchanged (RR, 0.92; 95% CI, 0.85, 1.00), but the heterogeneity was reduced (Q=52.88; P=0.196; I 2 =14.90).
MA interventions also reduced HF patients' risk of hospitalization (RR=0.89; 95% CI, 0.81, 0.97). However, only 32 treatment versus control studies contributed to the pooled estimate of RR. In order to include a larger number of studies in the hospitalization meta-analysis, we used the OR metric because 43 studies could provide data for the calculation of the overall effect (see Figure 5) . The pooled random-effects OR was 0.79 (95% CI, 0.71, 0.89). Again, the studies contained significant heterogeneity (Q=72.00; P=0.003; I 2 =41.66). In this analysis, 2 studies had significant residuals.
Removing those studies from the analysis gave an OR of 0.79 (95% CI, 0.73, 0.87) and reduced heterogeneity (Q=44.54; P=0.287; I 2 =10.19). Pooled analysis statistics for both mortality and hospitalization outcomes are reported in Table 4 . 
Risk of Bias Sensitivity Analyses
We conducted moderator analyses to evaluate whether ESs were different based on factors such as year of publication, presence of funding, study location, type of control group, randomization procedures, blinding, and use of intent-to-treat analyses (see Table 5 for list of report and methodological moderators analyzed). No significant ES differences were detected from any of the risk of bias analyses for either mortality or hospitalization outcomes.
Intervention and Sample Moderators
Although the studies tested many different types of interventions, only 2 intervention components showed significant ES differences in our moderator analyses (Table 6 ). For mortality outcomes, interventions that included components to improve health care providers' skills for addressing MA with their patients had a greater risk for mortality than did interventions not trying to improve health care provider adherence skills (RR, 1.50 vs 0.87; P=0.007). However, because only 4 studies' interventions included content to improve health care providers' adherence management skills, this finding must be interpreted carefully.
For hospitalization outcomes, interventions that did not include self-monitoring of patients' medication taking had a lower mean OR than did interventions using self-monitoring (OR, 0.76 vs 1.03; P=0.016). Other intervention components as well as sample moderators, such as sex, age, and race/ ethnicity, were tested for their influence on ES (see Table 5 ), but no significant differences were found.
Discussion
Our analyses found that interventions to improve adherence to medications for HF significantly reduce the risk for both hospitalization and death. The ESs for these outcomes were largely consistent across studies, with little heterogeneity in the overall ES estimates. In performing this analysis, we conducted a comprehensive search to include a broad spectrum of intervention studies. Previous meta-analyses of HF management programs have been more restricted in focus, examining distance-mediated interventions using telephone support or telemonitoring 73 Previous meta-analyses did not conduct moderator analyses to determine which intervention components were associated with larger ESs. In our project, we found that readmission outcomes were actually better when adherence interventions did not have patients self-monitoring their medication-taking behavior. A previous meta-analysis looking at adherence interventions among older adults found that selfmonitoring interventions were associated with increased MA ESs. 77 It is possible that for HF patients, self-monitoring of disease symptoms, such as daily weight measurement, may be more useful than monitoring medication taking to prevent hospital readmission. An interesting finding in this project was that interventions designed to train health care providers to have better skills for addressing MA actually resulted in a greater mortality risk for patients than did interventions not focusing on health care providers. This finding must be interpreted cautiously, given that only 4 studies included improving health care providers' skills for addressing adherence. Each of these 4 interventions also included a variety of other types of intervention components. Whereas health care provider skills and health care system interventions are important, interventions to improve MA must be patient centered. It is very difficult to modify patient behavior simply by modifying health care provider behavior, and a broader meta-analysis of health care provider interventions to improve MA found that whereas health care provider interventions are modestly effective, interventions must also include patient-centered approaches. 78 
Limitations
Any meta-analysis project is subject to certain limitations. First, it is always possible that some eligible studies may have not been identified through our searches. We used comprehensive search methods to identify as many eligible studies as possible and employed careful study-tracking procedures to avoid excluding any eligible studies. Meta-analyses are limited, however, by the primary research that has been conducted, methodological quality of the primary research, and quality of reporting of the primary studies. It is unknown whether otherwise eligible studies that were excluded because of inadequate data for calculating ESs might have impacted the overall ES.
Recommendations for Future Research
Room exists to develop interventions that further improve mortality and readmission risk for HF patients. Many MA interventions for HF patients are conducted as part of broader HF self-care interventions. No quantitative synthesis has yet summarized and compared effectiveness across HF self-care interventions to identify the most effective approach to improve HF outcomes. Furthermore, it is likely that the most effective approaches may differ for specific patient populations, a research question that may be further explored through meta-analysis. The lack of heterogeneity in mortality and readmission outcomes indicates that any intervention that successfully improves HF medication adherence is likely to improve mortality and readmission outcomes. Future research should investigate methods to assess adherence in clinical practice settings and integrate MA interventions into practice to improve clinical outcomes, and whether any type of additional attention may improve HF mortality and readmission rates.
Conclusion
Overall, interventions to improve adherence to HF medications lower risk for hospital readmission and overall mortality. MA is a key component of HF self-care and should be addressed as part of any HF self-care program. Room may exist for further improving MA interventions for HF patients, but the existing data show that the standard of care for addressing adherence in clinical practice can be improved to reduce HF morbidity and mortality. 
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